This design leverages MMP-22 overexpression in tumours: upon cleavage, TR3-M binds PD-L1 with high specificity, blocking PD-1/PD-L1 interactions between cancer cells and peripheral blood mononuclear cells (PBMCs) to restore antitumour immunity [142]. Here, CD274 is linked to neoplasm.